Kapil Dhingra is listed as a director on 3 SEC Form D filings by 1 issuer between Jul 2015 and Jul 2017: Exosome Diagnostics, Inc. (Waltham, MA — biotechnology — 2015–2017; $30.3M reported sold to 43 investors).
What this means One deal on file with the SEC. A Form D is the notice a company files after it starts selling a private investment — it is a notice, not an approval.
Listed alongside Geert-Jan Mulder (3 shared filings), Joseph Slattery (3 shared filings), Peter Johann (3 shared filings), Steven Soignet (3 shared filings), Thomas M. McLain (3 shared filings) and 3 others.
What this means These are the other officers, directors or promoters the companies named on the same forms — the team around Kapil. Each name links to their own page.
Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AZ, CA, DE, TX, WA) — none found.
What this means Nothing turned up where we looked (3 sources). That does not prove there is nothing — it means none was found in those sources on that date.
We compared 3 public filings for Kapil Dhingra and found 6 differences: Form D filed 17 days after the first sale; No amendment in the last 12 months on an offering that may still be open; and more below.
What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.